Navigation Links
Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
Date:4/19/2013

s (i.e., refractive lens exchange). OMS302 is added to standard irrigation solution used in ILR and delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to prevent surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will submit marketing applications for OMS302; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forw
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
(Date:7/30/2014)... 30, 2014 Company expands ... expertise to big data, aerospace and defense, medical, ... a leading engineering R&D services company, today announced ... GPU-powered solutions for aerospace and defense , ... (HPC), industrial , and visual computing ...
(Date:7/29/2014)... Calif., July 29, 2014 Amgen (NASDAQ: ... second quarter of 2014. Key results include: , ... 8 percent product sales growth driven by strong performance ... ® (carfilzomib), Prolia ® (denosumab) and XGEVA ... percent to $2.37, driven by higher revenues and a ...
Breaking Medicine Technology:Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... Beach, CA (PRWEB) July 30, 2014 ... hired new employees and continues to grow quickly. Chris’ ... Suite 260, Laguna Beach, across the street from Three ... intersection. , Previous to State Farm, Chris had ... Restaurant industry headquartered in Irvine, California, where his responsibilities ...
(Date:7/30/2014)... 30, 2014 It is said that necessity ... to be true as a product sponsor for Lash ... Vegas this past June. , Lash Affair believes ... success of the eyelash industry through collaboration so Jenelle Paris, ... have supported NEESA ’s event. Lash Affair’s mission dovetails ...
(Date:7/30/2014)... July 30, 2014 The global market ... million by 2020, growing at an estimated CAGR of ... study by Grand View Research, Inc. Growing global base ... is expected to serve this market as a primary ... 100% digital hearing aid technology and patient awareness levels ...
(Date:7/30/2014)... in every twenty elderly American adults is being financially ... burgeoning public health crisis especially affects poor and black ... researchers, and any citizen who cares about the dignity ... of Weill Cornell Medical College in the US. She ... elder abuse, the findings of which appear in the ...
(Date:7/30/2014)... A study of high school students by University of ... links between insomnia-related mental health conditions among teens. , ... surveyed more than 300 Australian high school students aged ... condition and the time of day they were most ... published in the journal Sleep Medicine ...
Breaking Medicine News(10 mins):Health News:State Farm Agent Chris Risi Is Celebrating His Agency's 1st Year Anniversary In September 2Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Older adults are at risk of financial abuse 2Health News:Teen insomnia is linked with depression and anxiety 2
... May 8 Large rallies in,Northern and ... a three-day,statewide unfair labor practice strike by ... medical facilities that succeeded in raising public,awareness ... Inter-Con,Security., (Photo: http://www.newscom.com/cgi-bin/prnh/20080508/DC21718 ), ...
... (May 8, 2008, Toronto, ON) Women suffering with ... psychotherapy from a specially trained nurse over the phone, ... the availability of a psychologist or psychiatrist. , Dr. ... at the Lawrence S. Bloomberg Faculty of Nursing, University ...
... ROTTERDAM, Netherlands, May 8 LyondellBasell Industries,has ... (HACCP),certification of its management systems at its ... where MonoPropyleneGlycol USP/EP,(MPG-USP/EP) is produced., HACCP ... on preventing,food safety hazards. The comprehensive nature ...
... 8 Covance Inc. (NYSE:,CVD) today announced that it ... "We are very pleased to have Joe Scodari ... 34-year career as a key leader in the,pharmaceutical and ... driving growth in large, complex global healthcare businesses,",said Joe ...
... lead to new, genetically targeted therapies , , ... about the molecular mechanisms that cause cardiac arrhythmia ... death has been uncovered by Rhode Island Hospital ... to the development of new, genetically targeted therapies ...
... INETICO, Inc. and TPABenefits, Inc.,of San Antonio, ... interface,between the INETICO system and the TPABenefits Web ... Claims Management, Pre-Certification,and Wellness data source and allows ... Pre-Certifications and Case Notes on the,TPABenefits Web Portal., ...
Cached Medicine News:Health News:Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices 2Health News:Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices 3Health News:Raising the Bar on MonoPropyleneGlycol USP/EP 2Health News:Covance Elects Joseph C. Scodari to Company's Board of Directors 2Health News:Study Offers Clues to Link Between Arrhythmia, Sudden Death 2Health News:INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution 2
The NOW® Flu B test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results an...
... Genetic Analyzer is an automated single-capillary genetic ... sequencing and fragment analysis applications. An affordable, ... who incorporate genetic analysis into their work., ... alternative to gel-based DNA analysis for any ...
... surgery represents one of the most technically ... Pelvic Plating System offers the highly specialized ... addressing fractures of the pelvis and acetabulum. ... as a premiere pelvic surgeon, is the ...
... The ACE Titanium Small Fragment System has ... surgeon with superior implants and user-friendly instrumentation. ... cannulated screws, and fracture instrumentation is designed ... armamentarium to utilize current and classic techniques ...
Medicine Products: